Blueprint Medicines (NASDAQ:BPMC) vs. CV Sciences (OTCMKTS:CVSI) Financial Contrast

Blueprint Medicines (NASDAQ:BPMC) and CV Sciences (OTCMKTS:CVSI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Blueprint Medicines and CV Sciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blueprint Medicines	1	6	12	1	2.65
CV Sciences	0	0	0	0	0.00

Blueprint Medicines currently has a consensus price target of $122.72, suggesting a potential upside of 17.00%. Given Blueprint Medicines’ stronger consensus rating and higher probable upside, research analysts clearly believe Blueprint Medicines is more favorable than CV Sciences.

Profitability

This table compares Blueprint Medicines and CV Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Blueprint Medicines	-29.48%	-112.30%	-26.87%
CV Sciences	-16.24%	-101.85%	-29.04%

Volatility & Risk

Blueprint Medicines has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, CV Sciences has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.

Valuation & Earnings

This table compares Blueprint Medicines and CV Sciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blueprint Medicines	$434.42 million	15.34	-$506.98 million	($2.11)	-49.71
CV Sciences	$16.00 million	0.39	$3.10 million	($0.01)	-3.40

CV Sciences has lower revenue, but higher earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than CV Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Blueprint Medicines beats CV Sciences on 7 of the 13 factors compared between the two stocks.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

About CV Sciences

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.